BIO 2026: Former FDA staff question agency’s “radical transparency” approach
The US Food and Drug Administration (FDA)’s “radical transparency” approach may have provided a more direct method, but it has…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
BIO 2026: How NIH cuts have threatened US competitiveness against China
Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese…
-
BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents
NVIDIA has unveiled the BioNeMo agent toolkit, a package of tools for life sciences R&D designed specifically for use by…
-
BIO 2026: Drug manufacturers band together to tackle employment challenges
US-based drugmakers are meeting rising demand not by competing for local talent, but by collaborating through trade associations to support…
-
Can AI predict the (regulatory) future?
The use of AI in pharma has expanded from pilots to function-specific projects with the development of more agile tools.…
-
Novo Nordisk puts AI at the centre of its clinical strategy
In the last few years, pharma leaders have been scrambling to see how artificial intelligence (AI) can augment every aspect…
-
AI-guided labs are approaching full autonomy
Taking a cue from the automotive industry, the biopharma sector has been increasingly focused on autonomous capabilities as a means…
-
Podcast: Autonomous labs redefine the role of biopharma researchers
Advances in robotics and artificial intelligence (AI) are leading to a rise of autonomous biopharma labs—entities that can undertake biomedical…
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming…
-
The innovators working to make in vivo cell therapy a reality
As investors signal early interest in in vivo cell therapies and raise the modality’s potential for commercial success, a growing…